GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vincerx Pharma Inc (NAS:VINC) » Definitions » Earnings Power Value (EPV)

Vincerx Pharma (Vincerx Pharma) Earnings Power Value (EPV) : $0.14 (As of Mar24)


View and export this data going back to 2020. Start your Free Trial

What is Vincerx Pharma Earnings Power Value (EPV)?

As of Mar24, Vincerx Pharma's earnings power value is $0.14. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is N/A.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.


Vincerx Pharma Earnings Power Value (EPV) Historical Data

The historical data trend for Vincerx Pharma's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vincerx Pharma Earnings Power Value (EPV) Chart

Vincerx Pharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Power Value (EPV)
- - - - -

Vincerx Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings Power Value (EPV) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vincerx Pharma's Earnings Power Value (EPV)

For the Biotechnology subindustry, Vincerx Pharma's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vincerx Pharma's Earnings Power Value (EPV) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vincerx Pharma's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where Vincerx Pharma's Earnings Power Value (EPV) falls into.



Vincerx Pharma Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.


Vincerx Pharma  (NAS:VINC) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.


Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.


Vincerx Pharma Earnings Power Value (EPV) Related Terms

Thank you for viewing the detailed overview of Vincerx Pharma's Earnings Power Value (EPV) provided by GuruFocus.com. Please click on the following links to see related term pages.


Vincerx Pharma (Vincerx Pharma) Business Description

Traded in Other Exchanges
N/A
Address
260 Sheridan Avenue, Suite 400, Palo Alto, CA, USA, 94306
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses to develop, use, manufacture, commercialize, sublicense and distribute a clinical-stage and follow-on small molecule drug program and a preclinical stage bioconjugation/next-generation ADC platform.
Executives
Alexander A. Seelenberger officer: Chief Financial Officer 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Raquel E. Izumi director, 10 percent owner, officer: Chief Operations Officer 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Ahmed Md Hamdy director, 10 percent owner, officer: President and CEO 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Tom C Thomas officer: See Remarks 180 LOMA ALTRO, C/O MOCON INC, LOS GATOS CA 95030
Christopher P. Lowe director 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
Laura I. Bushnell director 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Rubric Capital Management Lp 10 percent owner 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
David Efraim Rosen 10 percent owner 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Sooin Hwang officer: Chief Business Officer 260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306
Xiaoming Zhang officer: Chief Technology Officer 260 SHERIDAN AVE, SUITE 400, PALO ALTO CA 94306
Ruth E. Stevens director 260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306
Garban Hermes De Jesus officer: Chief Medical Officer 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
John C. Byrd 10 percent owner 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Brian Druker director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
John H. Lee director 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054

Vincerx Pharma (Vincerx Pharma) Headlines

From GuruFocus

Vincerx Pharma Provides Key Strategic Update

By GuruFocusNews GuruFocusNews 06-26-2022

Vincerx Pharma Provides Key Strategic Update

By GuruFocusNews GuruFocusNews 06-16-2022

Vincerx Pharma Provides Key Strategic Update

By GuruFocusNews GuruFocusNews 07-06-2022